Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival

CONCLUSIONS: Brachytherapy is an effective treatment for selected IR-PCA cases. Patients who were not eligible according to EAU/ESTRO/SIOG guidelines demonstrated a lower RFS.PMID:34484351 | PMC:PMC8407263 | DOI:10.5114/jcb.2021.108592

Source: Journal of Contemporary Brachytherapy - September 6, 2021 Category: Cancer & Oncology Authors: Sophie Robin Sylvie Chabaud Anne-Agathe Serre B éatrice Bringeon S ébastien Clippe Fran çois Rocher Olivier Desmettre Gabriel Bringeon Fr édéric Gassa Pascal Pommier Source Type: research